[AEGR] Aegerion Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.97 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart AEGR

Refresh chart

Description: Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company?s products include JUXTAPID (lomitapide) and LOJUXTA (lomitapide) hard capsules, an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia. It also has the right to use lomitapide in the field of monotherapy or in combination with other dyslipidemic therapies for treatment of patients with other severe forms of hypercholesterolemia. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-5.67 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 64.89% Sales Growth - Q/Q14.84% P/E-0.33
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-8.99% ROE-25.78% ROI-9.87%
Current Ratio3.63 Quick Ratio2.47 Long Term Debt/Equity2.38 Debt Ratio0.26
Gross Margin87.66% Operating Margin-10.75% Net Profit Margin-20.67% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities22.5 M Cash From Investing Activities-325.32 M Cash From Operating Activities-5.24 M Gross Profit47.55 M
Net Profit-15.82 M Operating Profit-9.18 M Total Assets438.69 M Total Current Assets141.9 M
Total Current Liabilities39.14 M Total Debt244.33 M Total Liabilities285.7 M Total Revenue59.38 M
Technical Data
High 52 week10.66 Low 52 week1.26 Last close1.97 Last change0%
RSI68.75 Average true range0.18 Beta1.05 Volume
Simple moving average 20 days3.3% Simple moving average 50 days-5.02% Simple moving average 200 days-16.23%
Performance Data
Performance Week0% Performance Month16.57% Performance Quart20.86% Performance Half43.8%
Performance Year-79.24% Performance Year-to-date0% Volatility daily1.56% Volatility weekly3.49%
Volatility monthly7.16% Volatility yearly24.81% Relative Volume0% Average Volume462.78 K
New High New Low

News

2016-11-29 17:08:53 | AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater

2016-11-29 12:10:33 | Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger Transaction; QLT to Change Name to Novelion Therapeutics Inc.

2016-11-17 16:58:13 | Aegerion Pharmaceuticals' JUXTAPID® lomitapide Capsules for the Treatment of Homozygous Familial Hypercholesterolemia HoFH Receives Pricing Authorization in Japan

2016-11-17 16:19:00 | 4:19 pm Aegerion Pharma announces that Japan's Ministry of Health, Labor & Welfare has approved pricing of JUXTAPID in Japan

2016-11-17 16:15:00 | Aegerion Pharmaceuticals’ JUXTAPID® lomitapide Capsules for the Treatment of Homozygous Familial Hypercholesterolemia HoFH Receives Pricing Authorization in Japan

2016-11-11 13:04:08 | AEGERION PHARMACEUTICALS, INC. Financials

2016-11-08 11:40:21 | ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : November 8, 2016

2016-11-07 17:40:19 | AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders

2016-11-07 11:38:24 | Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016

2016-11-04 11:41:05 | Aegerion Pharmaceuticals Appoints John Orloff, M.D., as Executive Vice President, Head of R&D

2016-11-04 09:32:01 | Aegerion AEGR Reports Narrower-than-Expected Loss in Q3

2016-11-03 19:32:53 | Aegerion reports 3Q loss

2016-11-03 17:21:09 | AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement

2016-11-03 16:21:38 | Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results

2016-11-03 16:05:00 | Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results

2016-11-02 10:36:02 | QLT's QLTI Reports In-Line Q3 Loss, Merger in Focus

2016-10-24 16:38:28 | AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events

2016-10-20 09:29:04 | ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : October 20, 2016

2016-10-20 08:05:46 | AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events

2016-10-03 16:03:24 | AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-09-28 16:19:02 | Aegerion Pharmaceuticals' JUXTAPID® lomitapide Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia HoFH

2016-09-28 16:05:00 | Aegerion Pharmaceuticals’ JUXTAPID® lomitapide Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia HoFH

2016-09-27 09:49:41 | ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : September 27, 2016

2016-09-24 08:25:02 | Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day

2016-09-20 08:58:04 | Aegerion Pharmaceuticals Appoints Remi Menes as Chief Commercial Officer

2016-09-20 08:50:00 | Aegerion Pharmaceuticals Appoints Remi Menes as Chief Commercial Officer

2016-09-14 13:36:00 | 5 Stocks Insiders Love Right Now

2016-09-13 10:14:41 | ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : September 13, 2016

2016-08-30 10:52:01 | ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : August 30, 2016

2016-08-24 07:08:00 | 7 Stocks Under $10 Making Big Up Moves

2016-08-12 14:05:55 | ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : August 12, 2016

2016-08-11 11:21:44 | Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016

2016-08-10 15:35:07 | Aegerion AEGR Q2 Loss Wider than Expected, View Intact

2016-08-09 18:28:58 | Aegerion reports 2Q loss

2016-08-09 17:00:07 | Aegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results

2016-08-09 16:12:05 | AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement

2016-06-15 08:49:04 | Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger

2016-06-15 07:09:06 | Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger

2016-06-07 17:08:05 | Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

2016-05-16 16:22:07 | Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results

2016-05-16 16:19:27 | Aegerion reports 1Q loss

2016-05-12 08:27:08 | Aegerion Pharmaceuticals Announces Preliminary Agreements in Principle With DOJ and SEC Related to Ongoing Investigations

2016-05-11 08:52:11 | Aegerion Pharmaceuticals to Announce First Quarter 2016 Financial Results on Monday, May 16

2016-05-06 08:34:05 | Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

2016-04-11 16:41:39 | Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

2016-03-31 08:09:10 | Aegerion Pharmaceuticals Observes World Lipodystrophy Day

2016-02-25 19:01:02 | Aegerion reports 4Q loss

2016-01-11 08:38:03 | Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates

2016-01-08 09:15:08 | Aegerion Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference

2016-01-07 09:52:03 | Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer